🔴 SAB Biotherapeutics is trading 5.5% down today amid biotech-sector weakness

SAB Biotherapeutics is trading at $2.67, down -5.48%, with biotech-sector weakness the clearest matching context.

• The XBI is down 2.01% during the regular session.
• SAB Biotherapeutics announced FDA Fast Track designation for SAB-142 on October 13; available reporting does not link it to the decline.
• SAB-142 is in a Phase 2b study, with topline data expected in 2H 2027.